Immunome (NASDAQ:IMNM) Rating Reiterated by Chardan Capital

Chardan Capital reissued their buy rating on shares of Immunome (NASDAQ:IMNM – Free Report) in a report released on Monday morning, PriceTargets.com reports. Chardan Capital also issued estimates for Immunome’s FY2023 earnings at ($0.77) EPS and FY2024 earnings at ($0.85) EPS.

Separately, Cantor Fitzgerald reiterated an overweight rating on shares of Immunome in a research note on Monday, May 15th.

Get Immunome alerts:

Immunome Stock Performance

NASDAQ:IMNM opened at $7.97 on Monday. The stock’s 50 day moving average price is $6.13 and its 200 day moving average price is $5.27. Immunome has a 52 week low of $2.20 and a 52 week high of $9.24. The company has a market capitalization of $97.31 million, a P/E ratio of -3.21 and a beta of 1.96.

Immunome (NASDAQ:IMNM – Get Free Report) last announced its earnings results on Friday, May 5th. The company reported ($0.35) earnings per share (EPS) for the quarter. The business had revenue of $2.36 million during the quarter.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Natixis bought a new position in shares of Immunome during the 4th quarter valued at about $25,000. UBS Group AG increased its holdings in shares of Immunome by 1,049.9% during the 3rd quarter. UBS Group AG now owns 15,271 shares of the company’s stock worth $68,000 after acquiring an additional 13,943 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Immunome by 53.6% during the 2nd quarter. Renaissance Technologies LLC now owns 21,500 shares of the company’s stock worth $69,000 after acquiring an additional 7,500 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Immunome during the 1st quarter worth approximately $77,000. Finally, HighTower Advisors LLC acquired a new position in shares of Immunome during the 1st quarter worth approximately $83,000. 14.46% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

(Get Free Report)

Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

Featured Stories

• Five stocks we like better than Immunome
• Delta Takes Flight: Double-Digit Upside In Sight
• Generac Powers Up as Summer Temperatures Rise
• 3 Reasons Why Rivian Can Continue To Surge Higher
• Despite Breaking Higher, Analysts Remain Cautious HP Inc.
• PepsiCo Can Soar To New Highs In The 2nd Half

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.